Carolyn J. Henry
Associate Professor of Oncology
    Department of Veterinary Medicine and Surgery, College of Veterinary Medicine
and Division of Hematology/Oncology, School of Medicine
Director, Tom and Betty Scott Endowed Program in Veterinary Oncology

· BS (magna cum laude), Eastern Kentucky University, Richmond, KY (dual majors of Animal Science and Biology, with a minor in Chemistry)
· DVM, (cum laude), Auburn University, Auburn, AL
· MS, (Small Animal Surgery and Medicine), Auburn University; Auburn, AL

· Diplomate, American College of Veterinary Internal Medicine (ACVIM) (Specialty of Oncology)
· Past President, Veterinary Cancer Society (www.vetcancersociety.org)

Email:  HenryC@missouri.edu

Research emphasis:

Research projects focus on investigations related to veterinary clinical and comparative oncology with a special interest in relevant models of human disease as they relate to earlier cancer detection and new drug development. Current areas of investigation include molecular markers of bladder cancer, novel therapies for canine mast cell tumors, lymphoma, bladder cancer, and hemangiosarcoma, and the use of Sm-153-EDTMP for limb salvage therapy of osteosarcoma.

Teaching:  Clinical Oncology

Selected publications:

Johannes CM, Henry CJ, Turnquist SE, Hamilton TA, Smith AN, Chun R, Tyler JW.  Hemangiosarcoma in cats: 53 cases (1992-2002).  J Am Vet Med Assoc. 2007; 231(12):1851-56.  [Abstract]

Henry CJ, Downing S, Rosenthal RC, Klein MK, Meleo K, Villamil JA, Fineman LS, McCaw DL, Higginbotham ML, McMichael J.  Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs.  Am J Vet Res. 2007; 68(11):1246-51.  [Abstract]

Johnson KD, Glinskii OV, Mossine VV, Turk JR, Mawhinney TP, Anthony DC, Henry CJ, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV.  Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia.  Neoplasia. 2007; 9(8):662-70.  [Abstract]

Bryan JN, Keeler MR, Henry CJ, Bryan ME, Hahn AW, Caldwell CW.  A population study of neutering status as a risk factor for canine prostate cancer.  Prostate. 2007; 67(11):1174-81.  [Abstract]

McCaw DL, Chan AS, Stegner AL, Mooney B, Bryan JN, Turnquist SE, Henry CJ, Alexander H, Alexander S.  Proteomics of canine lymphoma identifies potential cancer-specific protein markers.  Clin Cancer Res. 2007; 13(8):2496-503.  [Abstract]

Bryan JN, Henry CJ, Turnquist SE, Tyler JW, Liptak JM, Rizzo SA, Sfiligoi G, Steinberg SJ, Smith AN, Jackson T.  Primary renal neoplasia of dogs.   J Vet Intern Med. 2006; 20(5):1155-60.  [Abstract]

Johnson KD, Henry CJ, McCaw DL, Turnquist SE, Stoll MR, Kiupel M, Bondy PJ. Primary hyperaldosteronism in a dog with concurrent lymphoma. J Vet Med A Physiol Pathol Clin Med. 2006; 53(9):467-70.  [Abstract]

Bryan JN, Jia F, Mohsin H, Sivaguru G, Miller WH, Anderson CJ, Henry CJ, Lewis MR.  Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer.  Nucl Med Biol. 2005; 32(8):851-58.  [Abstract]

Henry CJ, Brewer WG Jr, Whitley EM, Tyler JW, Ogilvie GK, Norris A, Fox LE, Morrison WB, Hammer A, Vail DM, Berg J; Veterinary Cooperative Oncology Group (VCOG).  Canine digital tumors: a veterinary cooperative oncology group retrospective study of 64 dogs.  J Vet Intern Med 2005; 19(5):720-24.  [Abstract]

Weisse C, Soares N, Beal MW, Steffey MA, Drobatz KJ, Henry CJ.  Survival times in dogs with right atrial hemangiosarcoma treated by means of surgical resection with or without adjuvant chemotherapy: 23 cases (1986-2000). J Am Vet Med Assoc 2005; 226(4):575-79.  [Abstract]

Henry CJ, Buss MS, Hellstrom I, Hellstrom KE, Brewer WG, Bryan JN, Siegall CB. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.  Clin Cancer Res 2005; 11(2 Pt 1):751-55. [Abstract]

Dvorak LD, Beaver DP, Ellison GW, Bellah JR, Mann FA, Henry CJ.  Major glossectomy in dogs: a case series and proposed classification system. J Am Anim Hosp Assoc 2004; 40:331-37. [Abstract]

Bryan JN, Lewis MR, Henry CJ, Owen NK, Zhang J, Mohsin H, Jia F, Sivaguru G, Anderson CJ.  Development of a two-antibody model for the evaluation of copper-64 radioimmunotherapy. Vet Comp Oncol 2004; 2(2):82-90. [Abstract]

Cahalane AK, Payne S, Barber LG, Duda LE, Henry CJ, Mauldin GE, Frimberger AE, Cotter SM, Moore AS.  Prognostic factors for survival of dogs with inguinal and perineal mast cell tumors treated surgically with or without adjunctive treatment: 68 cases (1994-2002). J Am Vet Med Assoc 2004; 225(3):401-08.  [Abstract]

Henry CJ. Management of transitional cell carcinoma. Vet Clin North Amer: Sm Anim Pract 2003; 33(3):597-613. [Abstract]

Henry CJ, Tyler JW, McEntee MC, Stokol T, Rogers KS, Chun R, Garrett LD, McCaw DL, Higginbotham ML, Flessland KA, Stokes PK. Evaluation of a bladder tumor antigen test as a screening test for transitional cell carcinoma of the lower urinary tract in dogs. Am J Vet Res 2003;64(8):1017-20.  [Abstract]

Higginbotham ML, Henry CJ, Katti KV, Casteel SW, Dowling PM, Pillarsetty N. Preclinical tolerance and pharmacokinetic assessment of MU-Gold, a novel chemotherapeutic agent, in laboratory dogs. Vet Ther 2003; 4(1):76-82.  [Abstract]

Henry CJ, McCaw DL, Turnquist SE, Tyler JW, Bravo L, Sheafor S, Straw RC, Dernell WS, Madewell BR, Jorgensen L, Scott MA, Higginbotham ML, Chun R.  Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res 2003; 9(2):906-11. [Abstract]

Henry CJ, Russell LE, Tyler JW, Buss MS, Sequin B, Cambridge AJ, Moore ME.  Comparison of hematological and biochemical values for blood samples obtained via jugular venipuncture to those obtained via vascular access ports in cats. J Amer Vet Med Assoc 2002; 220(4):482-85.  [Abstract]

Moore AS, Nelson RW, Henry CJ, Rassnick KM, Kristal O, Ogilvie GK, Kintzer P.  Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 cases (1989-1999).  J Am Vet Med Assoc 2002; 221(6):811-18. [Abstract]

Clifford CA, Hughes D, Beal MW, Mackin AJ, Henry CJ, Shofer FS, Sorenmo KU.  Vascular endothelial growth factor concentrations in body cavity effusions in dogs.  J Vet Intern Med 2002;16(2):164-68.  [Abstract]

Henry CJ, McCaw DL, Brock KV, Stoker AM, Tyler JW, Tate DJ, Higginbotham ML. Association between cancer chemotherapy and cancer distemper virus, canine parvovirus, and rabies virus antibody titers in tumor-bearing dogs. J Am Vet Med Assoc 2001; 219(9):1238-1241.  [Abstract]

Henry CJ, McCaw DL, Buss MS, Pope ER, Tyler JW, Tate D, Russell L.  Clinical assessment of a chemosensitivity assay as a treatment planning tool for dogs with cancer.  J Amer Anim Hosp Assoc 2001; 37(2):165-171.  [Abstract]

Clifford CA, Mackin AJ, Henry CJ.  Treatment of canine hemangiosarcoma: 2000 and beyond.  J Vet Intern Med 2000; 14(5):479-485.  [Abstract]

Buss MS, Henry CJ, Tyler JW, Tobias KS, Daoud S, Hoopes J, Moore MP.  Systemic and tissue chamber fluid platinum concentrations released from cis-diamminedichloroplatinum II-impregnated polymethylmethacrylate in healthy dogs.  Am J Vet Res 1999; 60(3):280-83.  [Abstract]

Henry CJ, Turnquist SE, Smith A, Graham JC, Thamm DH, O'Brien M, Clifford CA. Primary renal tumors in cats: 19 cases (1992-1998).  J Feline Med Surg 1999; 1(3):165-70.  [Abstract]

MacEwen EG, Kurzman ID, Vail DM, Dubielzig RR, Madewell BR, Rodriguez CO, Phillips B, Zwahlen C, Obradovich J, Rosenthal RC, Fox LE, Rosenberg M, Henry CJ, Fidel J.  Adjuvant therapy for melanoma in dogs: Results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.  Clin Cancer Res 1999; 5(12): 4249-58.  [Abstract]

Henry CJ, Brewer WG, Tyler JW, Brawner WR, Henderson RA, Hankes GH, Royer N.  Survival in dogs with nasal adenocarcinoma: 64 cases (1981-1995).  J Vet Intern Med 1998; 12(6):436-39.  [Abstract]